Assertio Holdings Operating Expenses 2010-2024 | ASRT

Assertio Holdings operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Assertio Holdings Operating Expenses 2010-2024 | ASRT

Assertio Holdings operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$76.9B
Takeda Pharmaceutical (TAK)$43.9B
Merck (MKKGY)$20.8B
Astellas Pharma (ALPMY)$20.2B
Sandoz Group AG (SDZNY)$19.6B
United Therapeutics (UTHR)$17.7B
Summit Therapeutics (SMMT)$15.4B
Neurocrine Biosciences (NBIX)$12.7B
Shionogi (SGIOY)$12.3B
Catalent (CTLT)$10.9B
Madrigal Pharmaceuticals (MDGL)$7.4B
Jazz Pharmaceuticals (JAZZ)$6.9B
Orion OYJ (ORINY)$6.8B
Ionis Pharmaceuticals (IONS)$5.7B
Corcept Therapeutics (CORT)$5.7B
Crinetics Pharmaceuticals (CRNX)$4.7B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$3B
Catalyst Pharmaceuticals (CPRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Soleno Therapeutics (SLNO)$2.2B
NewAmsterdam Pharma (NAMS)$2B
Recursion Pharmaceuticals (RXRX)$2B
Centessa Pharmaceuticals (CNTA)$1.8B
Harrow (HROW)$1.7B
Ocular Therapeutix (OCUL)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.6B
Xencor (XNCR)$1.6B
Ardelyx (ARDX)$1.5B